Show simple item record

dc.contributor.authorLong, G
dc.contributor.authorBlank, C
dc.contributor.authorRibas, A
dc.contributor.authorMortier, L
dc.contributor.authorCarlino, M
dc.contributor.authorLotem, M
dc.contributor.authorLorigan, Paul C
dc.contributor.authorNeyns, B
dc.contributor.authorPetrella, T
dc.contributor.authorPuzanov, I
dc.contributor.authorRichtig, E
dc.contributor.authorO’Day, S
dc.contributor.authorMasucci, G
dc.contributor.authorLebbe, C
dc.contributor.authorSteven, N
dc.contributor.authorLutzky, J
dc.contributor.authorHille, D
dc.contributor.authorEbbinghaus, S
dc.contributor.authorIbrahim, N
dc.contributor.authorMcNeil, C
dc.date.accessioned2018-02-15T21:53:36Z
dc.date.available2018-02-15T21:53:36Z
dc.date.issued2017-02
dc.identifier.citationImpact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. 2017, 72:S122 Eur J Canceren
dc.identifier.issn09598049
dc.identifier.doi10.1016/S0959-8049(17)30482-3
dc.identifier.urihttp://hdl.handle.net/10541/620826
dc.language.isoenen
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0959804917304823en
dc.rightsArchived with thanks to European Journal of Canceren
dc.titleImpact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMelanoma Institute Australia, Medical Oncology, Sydneyen
dc.identifier.journalEuropean Journal of Canceren


Files in this item

This item appears in the following Collection(s)

Show simple item record